Display options
Cite
Hanson AC, Hagerman RJ. Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res. 2014;3(4):110-7doi: 10.5582/irdr.2014.01027.
Hanson, A. C., & Hagerman, R. J. (2014). Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable & rare diseases research, 3(4), 110-7. https://doi.org/10.5582/irdr.2014.01027
Hanson, Alicia C, and Hagerman, Randi J. "Serotonin dysregulation in Fragile X Syndrome: implications for treatment." Intractable & rare diseases research vol. 3,4 (2014): 110-7. doi: https://doi.org/10.5582/irdr.2014.01027
Hanson AC, Hagerman RJ. Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res. 2014 Nov;3(4):110-7. doi: 10.5582/irdr.2014.01027. PMID: 25606361; PMCID: PMC4298641.
Copy Download .nbib Format: NLM
Share it on

Intractable Rare Dis Res. 2014 Nov;3(4):110-7. doi: 10.5582/irdr.2014.01027.

Serotonin dysregulation in Fragile X Syndrome: implications for treatment.

Intractable & rare diseases research

Alicia C Hanson, Randi J Hagerman

Affiliations

  1. UC Davis School of Medicine, Sacramento, CA, USA;
  2. UC Davis MIND Institute and Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA.

PMID: 25606361 PMCID: PMC4298641 DOI: 10.5582/irdr.2014.01027

Abstract

Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.

Keywords: Fragile X Syndrome; fragile X mental retardation protein; selective serotonin reuptake inhibitors; sertraline

References

  1. Mol Cell Neurosci. 2013 Sep;56:39-49 - PubMed
  2. Ment Retard Dev Disabil Res Rev. 2004;10(1):42-8 - PubMed
  3. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17768-73 - PubMed
  4. J Neurosci. 2006 Jul 5;26(27):7151-5 - PubMed
  5. Neuropharmacology. 2014 Jan;76 Pt C:729-36 - PubMed
  6. Mol Autism. 2013 Jun 03;4(1):16 - PubMed
  7. Biol Psychiatry. 2012 Dec 1;72(11):924-33 - PubMed
  8. J Neurosci. 2010 Jun 30;30(26):8769-79 - PubMed
  9. J Neurophysiol. 2009 May;101(5):2572-80 - PubMed
  10. Eur J Pharmacol. 2010 Nov 25;647(1-3):90-6 - PubMed
  11. Psychopharmacology (Berl). 2013 Jul;228(1):75-84 - PubMed
  12. Neuron. 2008 Oct 23;60(2):201-14 - PubMed
  13. Annu Rev Pathol. 2012;7:219-45 - PubMed
  14. J Clin Sleep Med. 2009 Apr 15;5(2):145-50 - PubMed
  15. Front Cell Neurosci. 2013 Dec 19;7:260 - PubMed
  16. Neuroscience. 2012 Nov 8;224:223-34 - PubMed
  17. Front Cell Neurosci. 2014 May 28;8:150 - PubMed
  18. Arch Gen Psychiatry. 1996 Nov;53(11):993-1000 - PubMed
  19. J Neurosci. 2006 Dec 20;26(51):13218-30 - PubMed
  20. Drug Discov Today. 2009 Jul;14(13-14):690-7 - PubMed
  21. J Clin Invest. 2012 Dec;122(12):4314-22 - PubMed
  22. J Med Genet. 1995 Oct;32(10):764-9 - PubMed
  23. Neurobiol Dis. 2009 Feb;33(2):250-9 - PubMed
  24. Am J Ment Retard. 2008 Nov;113(6):427-38 - PubMed
  25. Autism Res Treat. 2012;2012:104317 - PubMed
  26. Neuron. 2013 Jan 23;77(2):243-50 - PubMed
  27. Biol Psychol. 2013 Feb;92(2):216-9 - PubMed
  28. Dev Neurosci. 2011;33(5):379-94 - PubMed
  29. J Neurodev Disord. 2011 Mar;3(1):57-67 - PubMed
  30. Psychopharmacology (Berl). 2014 Mar;231(6):1217-26 - PubMed
  31. Development. 2007 Dec;134(24):4369-80 - PubMed
  32. Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):null - PubMed
  33. Dev Neurobiol. 2012 Jun;72(6):755-65 - PubMed
  34. Am J Med Genet. 1999 Apr 2;83(4):268-79 - PubMed
  35. J Clin Psychiatry. 2014 Apr;75(4):e294-307 - PubMed
  36. Cell. 2003 Feb 7;112(3):317-27 - PubMed
  37. Synapse. 1998 Jan;28(1):33-43 - PubMed
  38. Neuropsychopharmacology. 2014 Dec;39(13):3100-11 - PubMed
  39. Pediatrics. 2009 Jan;123(1):378-90 - PubMed
  40. Nat Med. 2011 May;17(5):559-65 - PubMed
  41. Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17834-9 - PubMed
  42. PLoS Genet. 2010 Apr 08;6(4):e1000898 - PubMed
  43. Neuron. 2008 Aug 28;59(4):634-47 - PubMed
  44. J Autism Dev Disord. 2008 Jan;38(1):184-9 - PubMed
  45. Neuron. 2012 Apr 26;74(2):285-99 - PubMed
  46. Sleep. 2010 May;33(5):679-87 - PubMed
  47. J Autism Dev Disord. 2013 Jul;43(7):1676-91 - PubMed
  48. J Neurosci. 2011 Jan 26;31(4):1427-39 - PubMed
  49. Neurosci Lett. 2013 Aug 29;550:93-7 - PubMed
  50. Neurobiol Dis. 2002 Oct;11(1):221-9 - PubMed
  51. Pediatr Neurol. 2014 Apr;50(4):297-302 - PubMed
  52. J Psychopharmacol. 1998;12(3 Suppl B):S5-20 - PubMed
  53. Exp Neurol. 1994 Nov;130(1):31-40 - PubMed
  54. J Neural Transm (Vienna). 2014 Sep;121(9):1117-28 - PubMed
  55. Am J Med Genet. 2000 Summer;97(2):153-63 - PubMed
  56. Biomed Res Int. 2014;2014:195793 - PubMed
  57. Nat Med. 2013 May;19(5):603-7 - PubMed
  58. Exp Neurol. 2009 Feb;215(2):220-7 - PubMed
  59. Genes Brain Behav. 2012 Jul;11(5):513-23 - PubMed
  60. Neuropsychiatr Dis Treat. 2014 Sep 16;10:1769-79 - PubMed
  61. Am J Ment Retard. 2001 Sep;106(5):389-400 - PubMed
  62. Neurobiol Dis. 2011 Feb;41(2):469-80 - PubMed
  63. Neuropsychologia. 2000;38(9):1261-70 - PubMed
  64. Int J Psychophysiol. 2013 Apr;88(1):26-34 - PubMed
  65. Int J Dev Neurosci. 2005 Apr-May;23 (2-3):171-82 - PubMed
  66. Genes Dev. 2014 Feb 1;28(3):273-89 - PubMed
  67. Trends Neurosci. 2004 Jul;27(7):370-7 - PubMed
  68. J Neurosci. 2007 Oct 3;27(40):10685-94 - PubMed

Publication Types